{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:30:17Z","timestamp":1779222617899,"version":"3.51.4"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":1246,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>\n<jats:list list-type=\"explicit-label\">\n<jats:list-item><jats:p>Both spironolactone (SP) and its main metabolite, canrenoic acid (CA), prolong cardiac action potential duration and decrease the Kv11.1 (HERG) current. We examined the effects of SP and CA on cardiac hKv1.5, Kv4.3 and Kv7.1+minK channels that generate the human <jats:italic>I<\/jats:italic><jats:sub>Kur<\/jats:sub>, <jats:italic>I<\/jats:italic><jats:sub>to1<\/jats:sub> and <jats:italic>I<\/jats:italic><jats:sub>Ks<\/jats:sub>, which contribute to the control of human cardiac action potential duration.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>hKv1.5 currents were recorded in stably transfected mouse fibroblasts and Kv4.3 and Kv7.1+minK in transiently transfected Chinese hamster ovary cells using the whole\u2010cell patch clamp.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>SP (1\u2003<jats:italic>\u03bc<\/jats:italic><jats:sc>M<\/jats:sc>) and CA (1\u2003n<jats:sc>M<\/jats:sc>) inhibited hKv1.5 currents by 23.2\u00b13.2 and 18.9\u00b12.7%, respectively, shifted the midpoint of the activation curve to more negative potentials and delayed the time course of tail deactivation.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>SP (1\u2003<jats:italic>\u03bc<\/jats:italic><jats:sc>M<\/jats:sc>) and CA (1\u2003n<jats:sc>M<\/jats:sc>) inhibited the total charge crossing the membrane through Kv4.3 channels at +50\u2003mV by 27.1\u00b16.4 and 27.4\u00b15.7%, respectively, and accelerated the time course of current decay. CA, but not SP, shifted the inactivation curve to more hyperpolarised potentials (<jats:italic>V<\/jats:italic><jats:sub>h<\/jats:sub>\u221237.0\u00b11.8 vs \u221240.8\u00b11.6\u2003mV, <jats:italic>n<\/jats:italic>=10, <jats:italic>P<\/jats:italic>&lt;0.05).<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>SP (10\u2003<jats:italic>\u03bc<\/jats:italic><jats:sc>M<\/jats:sc>) and CA (1\u2003n<jats:sc>M<\/jats:sc>) also inhibited Kv7.1+minK currents by 38.6\u00b12.3 and 22.1\u00b11.4%, respectively, without modifying the voltage dependence of channel activation. SP, but not CA, slowed the time course of tail current decay.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>CA (1\u2003n<jats:sc>M<\/jats:sc>) inhibited the <jats:italic>I<\/jats:italic><jats:sub>Kur<\/jats:sub> (29.2\u00b15.5%) and the <jats:italic>I<\/jats:italic><jats:sub>to1<\/jats:sub> (16.1\u00b13.9%) recorded in mouse ventricular myocytes and the <jats:italic>I<\/jats:italic><jats:sub>K<\/jats:sub> (21.8\u00b16.9%) recorded in guinea\u2010pig ventricular myocytes.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>A mathematical model of human atrial action potentials demonstrated that K<jats:sup>+<\/jats:sup> blocking effects of CA resulted in a lengthening of action potential duration, both in normal and atrial fibrillation simulated conditions.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The results demonstrated that both SP and CA directly block hKv1.5, Kv4.3 and Kv7.1+minK channels, CA being more potent for these effects. Since peak free plasma concentrations of CA ranged between 3 and 16\u2003n<jats:sc>M<\/jats:sc>, these results indicated that blockade of these human cardiac K<jats:sup>+<\/jats:sup> channels can be observed after administration of therapeutic doses of SP.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Blockade of these cardiac K<jats:sup>+<\/jats:sup> currents, together with the antagonism of the aldosterone proarrhythmic effects produced by SP, might be highly desirable for the treatment of supraventricular arrhythmias.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic> (2005) <jats:bold>146<\/jats:bold>, 146\u2013161. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0706302\">10.1038\/sj.bjp.0706302<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/sj.bjp.0706302","type":"journal-article","created":{"date-parts":[[2005,6,27]],"date-time":"2005-06-27T09:23:34Z","timestamp":1119864214000},"page":"146-161","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Spironolactone and its main metabolite canrenoic acid block hKv1.5, Kv4.3 and Kv7.1+minK channels"],"prefix":"10.1111","volume":"146","author":[{"given":"Ricardo","family":"G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Delp\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s003950170002"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7793.2001.0151k.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-002-0377-4"},{"key":"e_1_2_7_5_1","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1152\/ajplegacy.1959.197.6.1161","article-title":"Antifibrillatory effects of electrolyte regulating steroids on isolated rabbit atria","volume":"197","author":"BRIGGS A.","year":"1959","journal-title":"Am. J. Physiol."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90239-9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2004.063446"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2004.063347"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.4.825"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2004.07.022"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000048189.58449.F7"},{"key":"e_1_2_7_12_1","first-page":"809","article-title":"Voltage\u2010 and time\u2010dependent block of the delayed K+ current in cardiac myocytes by dofetilide","volume":"262","author":"CARMELIET E.","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_13_1","first-page":"1038","article-title":"Bupivacaine inhibits the transient outward K+ current but not the inward rectifier in rat ventricular myocytes","volume":"255","author":"CASTLE N.A.","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.323"},{"key":"e_1_2_7_15_1","first-page":"128","article-title":"Effect of a spironolactone derivative, sodium canrenoate, on mechanical and electrical activities of isolated rat myocardium","volume":"191","author":"CORABOEUF E.","year":"1974","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(99)00034-6"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1987.tb11354.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.76.2.223"},{"key":"e_1_2_7_19_1","first-page":"1113","article-title":"Potassium channel blocking properties of propafenone in rabbit atrial myocytes","volume":"264","author":"DUAN D.","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(01)01905-1"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3109\/03602537808993782"},{"key":"e_1_2_7_22_1","first-page":"454","volume-title":"Cardiovascular Drug Therapy","author":"KIM K.E.","year":"1996"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.12.033"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc4601.099402"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg526"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000022665.18619.83"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.2004.00645.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.042325"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1540-8167.2002.00406.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00729-3"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.101.4.513"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/00045415-200203000-00008"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/16.suppl_N.103"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2003.12.026"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(02)00115-8"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.73.6.1061"},{"key":"e_1_2_7_38_1","first-page":"49","article-title":"Pharmacological receptors","volume":"20","author":"WAUD D.","year":"1968","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.11.11.9285481"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.93.3.407"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01243-8"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2003.07.027"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706302","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0706302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0706302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T21:24:06Z","timestamp":1697145846000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0706302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1038\/sj.bjp.0706302"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0706302","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}